InfuSystem Holdings, Inc. filed a formal investor presentation deck dated November 9, 2026, to provide a business update to investors. The presentation highlights the company's position as a home healthcare services platform and includes forward-looking statements regarding its growth initiatives and strategic partnerships.
InfuSystem Holdings, Inc. reported net revenues of $37.6 million for the third quarter of 2026, a 3% increase year-over-year, with net income rising to $3.2 million compared to $2.3 million in the prior year period. The company demonstrated improved operational efficiency with operating income growing 24.5% to $4.7 million, supported by a reduction in cost of revenues and strong gross profit margins.
InfuSystem Holdings reported Q3 2026 net revenues of $37.6 million, a 3% increase year-over-year, driven by strong growth in Oncology and Wound Care. Net income rose to $3.2 million, or $0.15 per diluted share, while Adjusted EBITDA margin expanded to 24.9%. The company reaffirmed its full-year 2026 guidance, expecting pro-forma revenue growth of 6% to 8%.
Term
Q3 2026
“We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform.”
Carrie Lachance, Chief Executive Officer
“Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment.”
InfuSystem Holdings, Inc. has postponed the release of its third quarter 2026 financial results to evaluate the accounting treatment of $4.2 million in ERP system implementation costs. The company is determining whether these costs should be capitalized and amortized over three years rather than expensed as incurred. Any resulting adjustment would be non-cash and would not impact the company's revenue or cash balances.